In non-small-cell lung cancer (NSCLC), EGFR mutations, ALK gene rearrangement, and alterations in the copy number of ROS-1 were related to increased risk of relapse or death in NSCLC patients, as well as to acquired resistance to ALK inhibitor in ALK-rearranged tumors [77,78,79,80,81,82,83]. Here, ALK is linked to non-small cell lung carcinoma.